# A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

Study · id `cardio:ct-nct06780410` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06780410](<https://clinicaltrials.gov/study/NCT06780410>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06780410

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

## Technical summary

Registry record NCT06780410. Randomized; double masking; primary purpose treatment. Start 2024-12-20 (actual); primary completion 2025-08-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 245 participants (enrolled count; ClinicalTrials.gov record NCT06780410, source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)
- Started: 2024-12-20 (actual) (ClinicalTrials.gov record NCT06780410, source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2025-08-05 (actual) (ClinicalTrials.gov record NCT06780410, source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)
- Completion: 2025-08-11 (actual) (ClinicalTrials.gov record NCT06780410, source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06780410, source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06780410-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
- Condition: Primary Hyperlipidemia
- Intervention (Drug): Bempedoic Acid Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Gan & Lee Pharmaceuticals.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry lists this organization as the lead sponsor: Gan & Lee Pharmaceuticals. (`cardio:org-gan-lee-pharmaceuticals`)

## Provenance

Content hash: 74b77e7905bf8ed24a0b0f9bc7766a6c057650dbf4ba40a7b93316cccb9be62a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
